TCRT - Alaunos Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

14.73M

Cash

18.32M

Avg Qtr Burn

-7.415M

Short % of Float

13.27%

Insider Ownership

8.86%

Institutional Own.

29.87%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TCR-T targeting neoantigens Details Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.